Company intelligence / Profile preview
Bonum Therapeutics
Seattle, WA, USAbonumtx.com ↗
- Ownership
- Private
- Employees
- ~33
- Development stage
- Preclinical
01
Overview
All current programs are preclinical. The company is advancing regulated cytokine therapies for oncology and other indications. No human clinical results have been reported as of early 2025.[10]
- Therapeutic areas
- OncologyImmunologyNeurologyMetabolic Disorders
- Modalities
- Protein therapeutics (regulated cytokines)Antibody-based therapeuticsImmunocytokines (antibody-cytokine fusion proteins)Large molecules[1][6][9]
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Roche Venture Fund (investor)seeking additional pharma/biotech collaborations but none announced as of May 2025.[6][9]
Beyond the preview
Go deeper on Bonum Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bonum Therapeutics.